Expression of heparanase, Mdm2, and erbB2 in ovarian cancer

被引:0
|
作者
Ginath, S
Menczer, J
Friedmann, Y
Aingorn, H
Aviv, A
Tajima, K
Dantes, A
Glezerman, M
Vlodavsky, I
Amsterdam, A [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Holon & Sackler Fac Med, Edith Wolfson Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel
关键词
heparanase; Mdm2; erbB2; apoptosis; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the most lethal of gynecological malignancies. Yet early diagnosis and prognosis are far from being satisfactory. Degradation of heparan sulfate proteoglycans by heparanase appears to play an important role in the invasiveness of tumor cells through the basement membrane and into the extracellular matrix. Recent cloning of the heparanase gene and generation of monoclonal antibodies against the enzyme permit to examine tumor cell expression of the enzyme. The aim of the present study was to assess heparanase activity and localization in various subtypes of epithelial ovarian cancer in correlation with oncogene expression. Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 and Mdm2. Heparanase immunohistostaining and activity were present in mucinous carcinomas and were more intense than in endometrioid and in serous carcinomas. The lowest activity was observed in benign ovarian tumors and normal ovaries. In ovarian carcinomas the enzyme was intensely concentrated in the cytoplasm of the cancerous cells. In contrast, in normal ovaries and benign tumors the enzyme was predominantly localized in endothelial cells lining blood capillaries. The rate of apoptosis was considerably higher in mucinous and endometrioid carcinomas, and was lower in serous and primary peritoneal carcinomas. Extremely high concentration of heparanase was often demonstrated in apoptotic cells. Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. In benign ovarian tumors and normal ovaries the expression of both oncoproteins was extremely low. In conclusion ovarian carcinomas demonstrate higher levels of heparanase than benign tumors and normal ovaries suggesting that the enzyme may play an important role in metastatic spread of the cancerous cells. Apoptosis may be a significant part of the mechanism of the enzyme release into the extacellular space. Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [31] Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression
    Tosios, Konstantinos I.
    Kalogirou, Eleni-Marina
    Koutlas, Ioannis G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [32] Gastric cancer: Differential expression of genes inside the ERBB2 amplicon
    Zaika, A
    Varis, A
    Knuutila, S
    Moskaluk, C
    El-Rifai, W
    GASTROENTEROLOGY, 2004, 126 (04) : A410 - A410
  • [33] FAS and ErbB2 expression in early local recurrent oral cancer
    Pinto, L. S. S.
    de Aguiar, F. C. A., Jr.
    Kowalski, L. P.
    Graner, E.
    Lopes, M. A.
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2010, 39 (02) : 176 - 181
  • [34] ErbB2 activation of ESX gene expression
    Neve, RM
    Ylstra, B
    Chang, CH
    Albertson, DG
    Benz, CC
    ONCOGENE, 2002, 21 (24) : 3934 - 3938
  • [35] INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes
    Pauley, RJ
    Gimotty, PA
    Paine, TJ
    Dawson, PJ
    Wolman, SR
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (01) : 65 - 76
  • [36] ErbB2 Activation of ESX gene expression
    Richard M Neve
    Bauke Ylstra
    Chuan-Hsiung Chang
    Donna G Albertson
    Christopher C Benz
    Oncogene, 2002, 21 : 3934 - 3938
  • [37] HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors
    Smithgall, Marie C.
    Yemelyanova, Anna
    Mathew, Susan
    Gogineni, Swarna
    He, Bing
    Zhang, Taotao
    Robinson, Brian D.
    Tu, Jiangling J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2024, 43 (02) : 134 - 139
  • [38] The Expression of MGMT and ErbB2 in Human Glioma
    Sun Chun-ming
    Wang Zhi-min
    Zheng Shi-ying
    Xu Qi-nian
    Zhang Shi-ming
    Zhou Dai
    2009 INTERNATIONAL CONFERENCE ON FUTURE BIOMEDICAL INFORMATION ENGINEERING (FBIE 2009), 2009, : 253 - +
  • [39] Amplification and expression of MDM2 in adult medulloblastoma
    Giordana, MT
    Schiffer, P
    Mauro, A
    Boghi, A
    Pradottó, L
    Morra, I
    BRAIN PATHOLOGY, 2000, 10 (04) : 685 - 685
  • [40] Abnormal expression of MDM2 in prostate carcinoma
    Leite, KRM
    Franco, MF
    Srougi, M
    Nesrallah, LJ
    Nesrallah, A
    Bevilacqua, RG
    Darini, E
    Carvalho, CM
    Meirelles, MI
    Santana, I
    Camara-Lopes, LH
    MODERN PATHOLOGY, 2001, 14 (05) : 428 - 436